In February 2026, my public trading portfolio maintained a +7% YTD return, despite a significant floating drawdown on short positions against the US Dollar (DXY). My core thesis centers on a “DXY Bottom,” driven by decade-low sentiment, AI-led efficiency deflation, and the upcoming Genius Act, targeting a recovery to the 105 level. 1. The Month’s […]
In February 2026, my February 2026 Portfolio underwent a strategic consolidation, emphasizing high-growth resilience. I increased positions in Microsoft (MSFT), Netflix (NFLX), and Constellation Software (CSU.TO), leveraging sector-specific volatility. While Bitcoin faced a -28% correction and Novo Nordisk retraced -22%, Netflix led with a +17.2% return. My strategy remains anchored in tiered entries and a
NVIDIA’s Q4 FY26 results confirm its absolute leadership in AI infrastructure, posting record revenue of $68.1 billion (+73% YoY) and net income of $43 billion. Despite a forward P/E of 18 for 2027, which appears to be a historic discount relative to growth, the absence of revenue from China and the potential cyclicality of software
In February 2026, financial markets are undergoing an irrational capitulation driven by AI-induced fear. While Big Tech (Microsoft, Amazon) is being penalized for a projected $650 billion Capex, software and service giants (Adobe, Visa, Booking) are plummeting on fears of technical obsolescence. However, Goldman Sachs data suggests that operational efficiency and new revenue streams from
Sprouts Farmers Market (SFM) is a dominant player in the health-focused grocery niche. With $8.8 billion in revenue in 2025 and 7.3% comparable store sales growth, the company operates with solid margins and aggressive share buybacks. Currently, following a 64% technical correction from its 2025 highs, SFM trades at a forward P/E of 11x, presenting
Novo Nordisk (NVO) shares plummeted over 21% in 48 hours following REDEFINE 4 trial data, where CagriSema showed a 23% weight loss compared to Eli Lilly’s Zepbound at 25.5%. Despite the market’s knee-jerk reaction, fundamental analysis reveals a 2026 P/E of 11x, a massive discount compared to Lilly’s 30x. With a robust pipeline including oral
